文献速递浆细胞疾病

伊沙妥昔单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的1b期研究

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood · 2017-05-08

这项1b期开放标签剂量递增研究评估了伊沙妥昔单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的安全性和疗效。57例患者接受治疗,伊沙妥昔单抗采用两种给药方案。最常见的伊沙妥昔单抗相关不良事件为输注相关反应(56%)。在可评估疗效人群中,总缓解率为56%(29/52),来那度胺难治患者中为52%。中位无进展生存期为8.5个月。

要点

  • 伊沙妥昔单抗联合来那度胺和地塞米松在复发/难治性多发性骨髓瘤中显示出活性且耐受性良好。
  • 最常见的伊沙妥昔单抗相关不良事件为输注相关反应(56%),多为1/2级。
  • 可评估疗效人群的总缓解率为56%(29/52),来那度胺难治患者中为52%。

核心结论

  • 伊沙妥昔单抗联合来那度胺和地塞米松在经重度治疗的复发/难治性多发性骨髓瘤患者中有活性且可耐受。

研究设计与样本

  • 1b期开放标签剂量递增研究,评估伊沙妥昔单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤。
  • 57例患者接受治疗,中位既往治疗方案数为5(范围1-12),83%对既往来那度胺治疗难治。
  • 伊沙妥昔单抗采用两种方案:每2周一次(Q2W)3、5或10 mg/kg;或每周一次(QW)10或20 mg/kg持续4周后改为每2周一次(QW/Q2W)。
  • 来那度胺25 mg(第1-21天)联合地塞米松40 mg(每周一次),28天为一周期。

主要发现

  • 中位给药持续时间为36.4周,数据截止时15例患者仍在治疗中。
  • 仅报告1例剂量限制性毒性(20 mg/kg QW/Q2W组3级肺炎),未达到最大耐受剂量。
  • 最常见的伊沙妥昔单抗相关不良事件为输注相关反应(56%),发生输注相关反应的患者中84%为1/2级,主要发生在首次输注期间。
  • 可评估疗效人群的总缓解率为56%(29/52),10 mg/kg Q2W组与10和20 mg/kg QW/Q2W组相似。
  • 42例可评估的来那度胺难治患者中总缓解率为52%,总体中位无进展生存期为8.5个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for 4 weeks and then Q2W thereafter [QW/Q2W]), in combination with lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM). Patients received 28-day treatment cycles; the primary objective was to determine the maximum tolerated dose (MTD) of isatuximab with lenalidomide and dexamethasone. Fifty-seven patients (median 5 [range 1-12] prior regimens; 83% refractory to previous lenalidomide therapy) were treated. Median duration of dosing was 36.4 weeks; 15 patients remained on treatment at data cutoff. Isatuximab-lenalidomide-dexamethasone was generally well tolerated with only 1 dose-limiting toxicity reported (grade 3 pneumonia at 20 mg/kg QW/Q2W); the MTD was not reached. The most common isatuximab-related adverse events were infusion-associated reactions (IARs) (56%), which were grade 1/2 in 84% of patients who had an IAR and predominantly occurred during the first infusion. In the efficacy-evaluable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts. The ORR was 52% in 42 evaluable lenalidomide-refractory patients. Overall median progression-free survival was 8.5 months. Isatuximab exposure increased in a greater than dose-proportional manner; isatuximab and lenalidomide pharmacokinetic parameters appeared independent. These data suggest that isatuximab combined with lenalidomide and dexamethasone is active and tolerated in heavily pretreated patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT01749969.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017. PMID: 28483761. doi:10.1182/blood-2016-09-740787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。